Quest Diagnostics Inc vs Roundhill S&P 500 0DTE Covered Call Strategy ETF — how do they compare? Quest Diagnostics Inc trades at $231.8 (market cap $25.48B), while Roundhill S&P 500 0DTE Covered Call Strategy ETF trades at $38.62 (market cap $330.98M). The key difference: Quest Diagnostics Inc is far larger — about 77× Roundhill S&P 500 0DTE Covered Call Strategy ETF's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while Roundhill S&P 500 0DTE Covered Call Strategy ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Roundhill S&P 500 0DTE Covered Call Strategy ETF for 54 Days on average.
| DGX | XDTE | |
|---|---|---|
Market Cap | $25.48B | $330.98M |
Volume | 941,866 | 194,030 |
Sector | Health | Income / Options Overlay |
52-Week High | $247.45 | $44.76 |
52-Week Low | $173.49 | $36.00 |
Typical Hold Time | 56 Days | 54 Days |
Enterprise Value | $31.23B | — |
Dividend Yield | 1.49% | — |
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $227.00, down 0.64% with a bearish technical signal. The company shows strong fundamentals with three consecutive quarterly earnings beats and revenue growth from $9.9B in 2024 to $11.0B in 2025. Recent developments include positive clinical study results and a new Apple Health integration, though Medicare reimbursement cuts pose headwinds. The stock trades near support at $226 with oversold RSI readings suggesting potential for near-term bounce.
DGX presents a mixed outlook with solid execution offset by regulatory risks. The 10% upside to consensus price target of $250 offers opportunity, but Medicare payment reductions and rising debt levels require monitoring. Recent earnings momentum and strategic partnerships support growth, making DGX suitable for investors comfortable with healthcare sector volatility.
No Aura AI signal available yet.
Trailing returns across standard periods
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →XDTE is an actively managed ETF that utilizes a synthetic covered call strategy on the S&P 500 Index using zero-days-to-expiration (0DTE) options. It seeks to provide high weekly income and overnight exposure to the index while mitigating some volatility through daily option premium harvesting.
Read more on XDTE →